glp-1 obesity drugs Medical Weight Loss Solutions GLP-1-based therapies for diabetes, obesity

Conclusion In summary, the results of this population based study, designed to closely emulate a randomised controlled trial, suggest that the use of the GLP-1 receptor agonist-SGLT-2 inhibitor combination is associated with a lower risk of major adverse cardiovascular events and serious renal events among patients with type 2 diabetes compared with each drug class alone

Miao Y, Guo D, Li W, Zhong Y

How can we guide them from thousands and thousands of studies that are done from different populations in different groups that starts to say the same concept, which is once again, whole, minimally processed foods are still healthy things and things that are round and have another circle in between arent going to be on any dietary guidelines as recommended foods

Mol Metab (2019) 30:72130

Now, the medical community is buzzing about the next evolutionary leap: Retatrutide

From curiosity-seekers trying to understand these new options to individuals actively seeking weight-loss solutions, a wide swath of internet users have been part of this surge